The Discovery Connection to Ferroptosis

When Brent Stockwell’s laboratory discovered erastin in 2003—a compound that selectively killed cancer cells with RAS mutations—they didn’t initially know how it worked. The cell death wasn’t apoptosis. The cells accumulated lipid peroxides and iron. And most tellingly, erastin’s effects could be reversed by adding cysteine to the culture medium.

This observation was the first clue that led to understanding ferroptosis. Erastin was blocking something that cells needed to import cysteine, and without cysteine, cells couldn’t make enough glutathione to fuel GPX4, leading to lipid peroxidation and death. That “something” was system xc- (pronounced “system x-c-minus”), a membrane transporter that became recognized as a critical gatekeeper of ferroptosis sensitivity.

System xc- is the cystine/glutamate antiporter that sits at the very beginning of the ferroptosis defense cascade. By controlling cysteine availability, it determines whether cells can synthesize enough glutathione to keep GPX4 functioning. When system xc- is blocked, the entire GPX4-dependent ferroptosis defense system collapses.

What is System Xc-?

System xc- is a membrane transport protein that exchanges amino acids across the cell membrane. Specifically, it imports one molecule of cystine (the oxidized, disulfide form of cysteine) into the cell while simultaneously exporting one molecule of glutamate out of the cell. This 1:1 exchange is electroneutral and sodium-independent, meaning it doesn’t require cellular energy.

The Exchange:

• Import: Cystine (Cys-S-S-Cys) enters the cell
• Export: Glutamate (Glu) leaves the cell
• Ratio: 1:1 antiport (one in, one out)

Why This Matters for Ferroptosis:

Once inside the cell, cystine is rapidly reduced to two molecules of cysteine. Cysteine is the rate-limiting substrate for glutathione (GSH) synthesis. Without adequate cysteine, cells cannot make enough GSH, and without GSH, GPX4 cannot reduce lipid hydroperoxides. The result: lipid peroxidation accumulates and ferroptosis occurs.

System xc- is therefore the first critical step in a cascade:

1. System xc- imports cystine
2. Cystine → cysteine (reduced inside cells)
3. Cysteine → glutathione synthesis
4. GSH fuels GPX4 activity
5. GPX4 prevents lipid peroxidation
6. Cell survives ferroptosis

Molecular Composition: A Two-Subunit Transporter

System xc- is a heterodimeric protein composed of two subunits linked by a disulfide bond:

SLC7A11 (xCT) – The Light Chain:

• Also called xCT
• 12 transmembrane domains
• Provides the transport activity
• Substrate specificity for cystine and glutamate
• The functional, catalytic subunit
• This is the subunit most commonly referred to when discussing system xc- in ferroptosis

SLC3A2 (4F2hc/CD98) – The Heavy Chain:

• Also called 4F2hc or CD98
• Single transmembrane domain
• Chaperone function: helps SLC7A11 properly fold and traffic to the cell membrane
• Required for SLC7A11 stability and membrane localization
• Shared with other amino acid transporters (not specific to system xc-)

The Partnership: Both subunits are necessary for functional system xc-. SLC7A11 provides the transport activity, while SLC3A2 ensures SLC7A11 gets to the cell membrane and functions properly. However, SLC7A11 is the rate-limiting component and the primary target of ferroptosis-inducing compounds.

SLC7A11: The Key Subunit

When researchers and papers discuss “system xc-” in the context of ferroptosis, they’re almost always referring to SLC7A11 specifically, since:

• SLC7A11 expression determines system xc- activity
• SLC7A11 is the target of erastin and other ferroptosis inducers
• SLC7A11 expression varies widely between cell types
• Transcriptional regulation primarily targets SLC7A11
• SLC7A11 levels predict ferroptosis sensitivity

Gene and Protein:

• Gene name: SLC7A11 (solute carrier family 7 member 11)
• Protein name: xCT
• Chromosome location: Human chromosome 4q28.3
• Size: ~500 amino acids

How System Xc- Works: The Transport Mechanism

System xc- operates through an obligatory exchange mechanism—it cannot import cystine without simultaneously exporting glutamate, and vice versa.

Step 1: Substrate Binding The transporter binds both cystine (on the outside) and glutamate (on the inside) before any movement occurs.

Step 2: Conformational Change The transporter undergoes a conformational change that simultaneously:

• Moves cystine from outside to inside
• Moves glutamate from inside to outside

Step 3: Release and Reset Substrates are released, and the transporter returns to its original conformation, ready for another cycle.

Key Features:

• Strict 1:1 exchange: Cannot transport one without the other
• High affinity for cystine: Km ~80-100 μM (efficiently captures even low extracellular cystine)
• Electroneutral: No net charge movement
• Sodium-independent: Doesn’t require Na+ gradient (unlike many transporters)

Cystine Reduction and Glutathione Synthesis

After Import:

Once cystine enters the cell through system xc-, it’s rapidly reduced to cysteine:

Cystine (Cys-S-S-Cys) + reducing equivalents → 2 Cysteine (Cys-SH)

This reduction is mediated by cellular reducing systems including:

• Thioredoxin reductase
• NADPH-dependent reductases
• Glutathione (creating a positive feedback loop)

Glutathione Synthesis:

Cysteine is the rate-limiting substrate for glutathione synthesis, which occurs in two ATP-dependent steps:

1. γ-Glutamylcysteine synthetase (GCL): Glutamate + Cysteine → γ-Glutamylcysteine
2. Glutathione synthetase (GS): γ-Glutamylcysteine + Glycine → Glutathione (GSH)

Why Cysteine is Rate-Limiting:

• Glutamate and glycine are abundant
• Cysteine is relatively scarce
• Cysteine availability fluctuates with system xc- activity
• GCL has high affinity for cysteine, so even small changes in cysteine levels affect GSH synthesis

Erastin: The Prototypical System Xc- Inhibitor

Erastin was the compound that led to the discovery of ferroptosis and the first identified system xc- inhibitor.

Mechanism: Erastin directly binds to and inhibits system xc- (specifically the SLC7A11 subunit), blocking cystine import. This was initially mysterious—researchers knew erastin killed cells but didn’t know how. The breakthrough came when they discovered:

1. Erastin blocks cystine uptake
2. Cystine depletion → cysteine depletion
3. Cysteine depletion → GSH depletion
4. GSH depletion → GPX4 cannot function
5. GPX4 failure → lipid peroxidation → ferroptosis

Properties:

• Selective for cancer cells (especially RAS-mutant)
• Non-toxic to normal cells at effective concentrations
• Effects completely reversed by:
  • β-mercaptoethanol (provides reducing equivalents)
  • N-acetylcysteine (provides cysteine)
  • Ferrostatin-1 (lipid antioxidant)

Research Use: Erastin remains the most commonly used ferroptosis inducer in research, serving as the gold standard for inducing system xc- blockade and ferroptosis in cell culture.

Other System Xc- Inhibitors

Sulfasalazine (SAS):

• FDA-approved anti-inflammatory drug
• Inhibits system xc- as off-target effect
• Used clinically for inflammatory bowel disease and rheumatoid arthritis
• Can induce ferroptosis in some cancer cells
• Less potent than erastin but clinically available

Sorafenib:

• FDA-approved multi-kinase inhibitor for kidney and liver cancer
• Originally developed as a kinase inhibitor
• Also inhibits system xc- (off-target effect)
• Can induce ferroptosis in hepatocellular carcinoma
• Mechanism of anti-cancer activity may partly involve ferroptosis

Glutamate:

• High extracellular glutamate competitively inhibits cystine uptake
• Since system xc- exports glutamate, high external glutamate opposes this export
• This indirectly reduces cystine import
• Relevant in glutamate excitotoxicity and certain disease states

Tissue and Cell Type Expression

System xc- (SLC7A11) expression varies dramatically across tissues and cell types:

High Expression:

• Brain: Particularly astrocytes and certain neuronal populations
• Immune cells: Macrophages, dendritic cells
• Pancreatic β-cells: High susceptibility to ferroptosis
• Many cancer types: Upregulated as survival mechanism

Moderate Expression:

• Kidney tubular cells
• Some epithelial tissues
• Fibroblasts

Low/Absent Expression:

• Skeletal muscle
• Cardiac muscle
• Many differentiated cell types

Functional Significance:

Expression levels determine ferroptosis sensitivity:

• High SLC7A11 = High cystine import = High GSH = Ferroptosis resistant
• Low SLC7A11 = Low cystine import = Low GSH = Ferroptosis sensitive

This creates therapeutic opportunities: cancers with high SLC7A11 are good targets for system xc- inhibition.

Transcriptional Regulation of SLC7A11

SLC7A11 expression is tightly controlled by multiple transcription factors:

Positive Regulators (Increase SLC7A11):

NRF2 (Nuclear factor erythroid 2-related factor 2):

• Master antioxidant transcription factor
• Binds to antioxidant response elements (AREs) in SLC7A11 promoter
• Strongly upregulates SLC7A11 in response to oxidative stress
• NRF2 activation → increased SLC7A11 → ferroptosis resistance
• This is the most important positive regulator

ATF4 (Activating transcription factor 4):

• Stress-responsive transcription factor
• Upregulates SLC7A11 during amino acid starvation and ER stress
• Provides stress-induced ferroptosis protection

Negative Regulators (Decrease SLC7A11):

p53 (Tumor suppressor):

• Directly represses SLC7A11 transcription
• Provides one mechanism by which p53 promotes ferroptosis
• p53 activation → decreased SLC7A11 → ferroptosis sensitivity
• Important for p53-mediated tumor suppression

BAP1 (BRCA1-associated protein 1):

• Tumor suppressor and deubiquitinase
• Represses SLC7A11 expression
• BAP1 loss → increased SLC7A11 → ferroptosis resistance in some cancers

Context-Dependent Regulation:

The balance between these regulators determines SLC7A11 levels:

• Cancer cells often have high NRF2 and low p53 → high SLC7A11 → ferroptosis resistant
• Stress conditions activate ATF4 and NRF2 → transiently increase SLC7A11
• Tumor suppression via p53 → decreases SLC7A11 → promotes ferroptosis

The Glutamate Consequence: Excitotoxicity Connection

System xc- doesn’t just import cystine—it exports glutamate. This has important physiological and pathological consequences:

Normal Function: In the brain, astrocytes use system xc- to:

• Import cystine for GSH synthesis (protecting against oxidative stress)
• Export glutamate into extracellular space
• This glutamate is normally cleared by glutamate transporters

The Problem:

High system xc- activity can lead to glutamate accumulation in extracellular space, which can cause:

• Excitotoxicity: Excessive activation of glutamate receptors (especially NMDA receptors)
• Neuronal damage: Overactivation of neurons leading to calcium overload and cell death
• Seizures: In extreme cases

Clinical Relevance:

This creates a paradox in the brain:

• System xc- protects cells from ferroptosis (via cystine import)
• But system xc- can harm neurons (via glutamate export)

In glioblastoma, high system xc- expression:

• Protects tumor cells from ferroptosis
• Creates glutamate excitotoxicity that kills surrounding normal neurons
• Contributes to seizures in glioma patients
• Makes system xc- an attractive therapeutic target

System Xc- in Cancer

Cancer cells frequently upregulate system xc- as a survival mechanism:

Why Cancer Cells Need High System Xc-:

1. High metabolic rate generates more oxidative stress → need more GSH
2. Rapid proliferation increases oxidative burden
3. Harsh tumor microenvironment (hypoxia, low nutrients) → stress response
4. Resistance to therapy many chemotherapies generate ROS

Mechanism of Upregulation:

Cancers often have:

• NRF2 pathway activation (KEAP1 mutations, NRF2 mutations)
• p53 loss or mutation (removes negative regulation)
• Oncogenic signaling that activates NRF2

Therapeutic Implications:

System xc- as a Target:

• Cancers with high SLC7A11 are vulnerable to system xc- inhibition
• Inducing ferroptosis by blocking system xc-
• Combining with other therapies that generate oxidative stress

Biomarker Potential:

• SLC7A11 expression predicts:
  • Ferroptosis sensitivity
  • Response to certain chemotherapies
  • Prognosis in some cancer types

Resistance Mechanism:

• Cancers can adapt to system xc- inhibition by:
  • Upregulating alternative cysteine sources (transsulfuration pathway)
  • Increasing FSP1 or GCH1 expression (alternative ferroptosis defenses)
  • Reducing ACSL4/LPCAT3 (decreasing lipid vulnerability)

System Xc- in the Brain

The brain has unique relationships with system xc-:

Astrocyte Expression: Astrocytes highly express system xc- because they:

• Face high oxidative stress (supporting neurons)
• Need abundant GSH for neuroprotection
• Export glutamate that’s usually cleared appropriately

Neuronal Vulnerability: Neurons generally have lower system xc- expression:

• More vulnerable to cysteine deprivation
• More susceptible to ferroptosis
• Depend partly on astrocyte GSH export

Disease Connections:

Glioblastoma:

• Tumor cells hijack system xc-
• Excess glutamate release kills neurons (excitotoxicity)
• Protects tumor from ferroptosis
• Contributes to seizures
• System xc- inhibitors show promise

Stroke:

• Ischemia depletes cysteine and GSH
• Reperfusion can trigger ferroptosis
• System xc- activity affects stroke outcome
• Context-dependent: helpful for GSH synthesis, harmful if causing glutamate excess

Alzheimer’s and Parkinson’s:

• Oxidative stress is prominent
• System xc- dysfunction implicated
• May contribute to ferroptosis in neurodegeneration

Alternative Cysteine Sources: The Transsulfuration Pathway

While system xc- is the major cysteine source for many cells, there’s an alternative: the transsulfuration pathway.

The Pathway: Methionine → Homocysteine → Cystathionine → Cysteine

Key Enzymes:

• Cystathionine β-synthase (CBS)
• Cystathionine γ-lyase (CSE)

When It Matters:

Some cells can produce cysteine internally via transsulfuration:

• Liver (high transsulfuration capacity)
• Some cancer cells adapt by upregulating this pathway
• Can provide ferroptosis resistance even when system xc- is blocked

Therapeutic Relevance:

For effective ferroptosis induction in some cancers, you may need:

• System xc- inhibition (blocks external cysteine)
• Plus transsulfuration pathway inhibition (blocks internal cysteine)
• Dual blockade maximizes cysteine deprivation

Measuring System Xc- Activity

Functional Assays:

Cystine Uptake:

• Measure radioactive ³⁵S-cystine uptake into cells
• Most direct measure of system xc- transport activity

Glutamate Release:

• Measure glutamate in culture medium
• Indirect measure (glutamate release = cystine import)

Expression Measurement:

qPCR:

• Measure SLC7A11 mRNA levels
• Quick and sensitive

Western Blot:

• Measure SLC7A11 protein levels
• Correlates better with function than mRNA

Immunohistochemistry:

• Visualize SLC7A11 in tissues
• Spatial information about expression

Functional Outcomes:

GSH Levels:

• Measure total glutathione
• Downstream consequence of system xc- activity

Ferroptosis Sensitivity:

• Treat with erastin and measure cell death
• Ultimate functional readout

Pharmacological Manipulation

Inhibiting System Xc-:

Small Molecules:

• Erastin: Research standard, potent, not clinically available
• Sulfasalazine: FDA-approved, can be repurposed
• Sorafenib: FDA-approved kinase inhibitor with system xc- inhibition

Genetic:

• SLC7A11 knockout/knockdown: Complete system xc- loss
• Dominant-negative mutants: Research tools

Activating System Xc-:

Less commonly done, but possible:

• NRF2 activators: Indirectly increase SLC7A11 expression
• Useful for neuroprotection strategies

System Xc- and Other Ferroptosis Pathways

System xc- is part of the GPX4-dependent ferroptosis defense but interacts with other pathways:

Relationship to GPX4:

• System xc- → cysteine → GSH → GPX4 activity
• Direct linear pathway
• System xc- is “upstream” of GPX4

Relationship to FSP1-CoQ10:

• Independent pathways
• FSP1 doesn’t require cysteine or GSH
• Cells can survive system xc- inhibition if FSP1 is high

Relationship to GCH1-BH4:

• Also independent
• BH4 synthesis doesn’t require cysteine
• Another escape route from system xc- inhibition

Therapeutic Implication:

For maximal ferroptosis induction in resistant cancers:

• Block system xc- (erastin, sulfasalazine)
• And inhibit FSP1
• And inhibit GCH1
• Triple blockade eliminates redundancy

Clinical Translation: Challenges and Opportunities

Opportunities:

Repurposing Approved Drugs:

• Sulfasalazine already FDA-approved
• Sorafenib already used for cancer
• Safety profiles established

Biomarker-Driven Therapy:

• Test tumors for SLC7A11 expression
• High expression → good candidates for system xc- inhibition
• Personalized medicine approach

Combination Strategies:

• System xc- inhibitors + other ferroptosis inducers
• System xc- inhibitors + chemotherapy/radiation
• Sensitize resistant tumors

Challenges:

Selectivity:

• How to inhibit tumor system xc- without affecting normal tissues?
• Brain particularly sensitive due to glutamate toxicity concerns

Resistance:

• Tumors adapt via alternative cysteine sources
• Upregulation of FSP1, GCH1, or other defenses
• Need combination approaches

Delivery:

• Getting inhibitors to tumor site
• Brain penetration for gliomas

Toxicity:

• Glutamate-related neurotoxicity
• Oxidative stress in normal tissues
• Need careful dose optimization

System Xc- in Other Diseases

Inflammatory Diseases:

System xc- has roles beyond cancer:

• Inflammatory bowel disease: Sulfasalazine’s therapeutic effects partly through system xc-
• Rheumatoid arthritis: Oxidative stress and inflammation
• Asthma: Oxidative stress component

Metabolic Diseases:

Diabetes:

• Pancreatic β-cells have high system xc- expression
• Vulnerable to ferroptosis when system xc- is inhibited
• May contribute to β-cell loss in diabetes

Cardiovascular Disease:

• Oxidative stress in atherosclerosis
• System xc- in vascular cells
• Balance of protection vs. pathology

Current Research Directions

Outstanding Questions:

• How do cells decide between system xc- and transsulfuration pathways?
• What determines SLC7A11 expression heterogeneity within tumors?
• Can we develop tumor-selective system xc- inhibitors?
• How does system xc- regulation differ across cell types?
• What are all the post-translational modifications that regulate SLC7A11?

Emerging Areas:

• Single-cell analysis: Understanding SLC7A11 expression heterogeneity
• Drug development: Novel, more selective system xc- inhibitors
• Combination therapies: Optimal partners for system xc- blockade
• Biomarker validation: Clinical trials testing SLC7A11 as predictor
• Spatial biology: Where in tumors is SLC7A11 highest?

Key Takeaways

System xc- is the gatekeeper of ferroptosis defense:

• It imports cystine, enabling glutathione synthesis and GPX4 function
• Composed of SLC7A11 (functional subunit) and SLC3A2 (chaperone)
• Erastin’s discovery as system xc- inhibitor led to understanding ferroptosis
• Expression varies widely; high expression confers ferroptosis resistance
• Transcriptionally regulated by NRF2 (positive) and p53 (negative)
• Highly expressed in many cancers as survival mechanism
• Creates glutamate-related complications in the brain
• Therapeutic target for ferroptosis-based cancer therapy
• Part of GPX4-dependent defense; independent of FSP1 and GCH1
• Alternative cysteine sources (transsulfuration) can provide resistance

Understanding system xc- reveals how a single transporter can be a critical determinant of cell fate, connecting amino acid metabolism, redox homeostasis, and cell death. Its position at the beginning of the ferroptosis defense cascade makes it both a valuable therapeutic target and a key regulator of cellular responses to oxidative stress.